Background-Rheumatoid arthritis (RA) is characterized by increased cardiovascular morbidity and mortality that cannot be explained solely by traditional cardiovascular risk factors. Cardiovascular morbidity is related to disease activity and can be normalized by effective therapy. Because the quantity of endothelial progenitor cells (EPCs) in the peripheral blood is correlated inversely with cardiovascular risk, we studied whether such abnormalities could also be observed in patients with RA. Methods and Results-EPCs were determined in 52 RA patients and in 16 healthy referents (HRs) by fluorescence-activated cell-sorting (FACS) analysis. Patients were divided into groups characterized by active disease (nϭ36) and low disease activity (nϭ16). Cells that were positive by flow cytometry for CD34/KDR/AC133 within the lymphocyte population were characterized as EPCs. Furthermore, in subgroups of patients, circulating EPCs were also quantified by a colony-forming unit (CFU) and a circulating angiogenic cell (CAC) assay. 
R
heumatoid arthritis (RA) is characterized by increased cardiovascular morbidity and mortality 1, 2 that cannot be explained by traditional cardiovascular risk factors alone. 3 It has been suggested that the enhanced cardiovascular risk is caused by the permanent overexpression of cellular adhesion molecules and proinflammatory cytokines in the context of chronic inflammation. 4 Such events are supposed to be important triggers for plaque formation leading to atherosclerosis and stenosis of the coronary and peripheral arteries. Furthermore, recent evidence suggests that C-reactive protein (CRP), matrix metalloproteinase-9, and the proinflammatory cytokine interleukin-18, all elevated in RA and potentially essential in RA pathogenesis, are involved in the development of atherosclerosis. 5, 6 Importantly, effective diseasemodifying antirheumatic drug (DMARD) therapy of RA may reduce the cardiovascular risk associated with the disease, 7 and the vascular dysfunction that can already be observed in early stages of the disease 8 has been shown to be improved by blockade of tumor necrosis factor (TNF). 9 RA is associated with enhanced angiogenesis. The inflamed synovial membrane is characterized by intense vascularization, 10 -12 which is essential for synovial expansion and pannus formation. 13 This altered vessel formation is also reflected by an increase in proangiogenic molecules, like vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), in the sera and synovial fluid of RA patients. 14 -18 Moreover, VEGF serum concentrations were also shown to be associated with disease activity. 19 Generally, in the adult human organism, new blood vessel formation can occur in 2 ways: by endothelial sprouting from preexisting endothelial cells/angioblasts (angiogenesis) or by peripheral recruitment of endothelial progenitor cells (EPCs) (vasculogenesis). 20 EPCs, primarily described in the landmark observation of Asahara et al, 21 represent a population of bone marrow-derived, CD34-, VEGF receptor-2 (VEGFR-2 or kinase-insert domain receptor [KDR])-, AC133-positive cells 22 that have the ability to differentiate into endothelial cells and thus, make a significant contribution to new blood vessel formation. 23 It has long been thought that EPCs could be cultured from peripheral blood mononuclear cells (PBMCs) on fibronectin and then express receptors for LDL and lectin. 21 However, recent observations indicate that these cultured cells are mainly monocyte/leukocyte-derived entities 24, 25 ; nevertheless, they also contribute to angiogenesis by secreting proangiogenic factors and are now referred to as circulating angiogenic cells (CACs). 24 The number of circulating EPCs and CACs has been described to be inversely correlated with several risk factors for coronary artery disease and to constitute a surrogate marker for various aspects of vascular function. 26 -29 On the basis of all these observations, we hypothesized that there might be an alteration of circulating EPCs and CACs in RA.
Methods

Characteristics of Study Patients and HR Subjects
EPCs were studied by FACS analysis from 52 random patients suffering from RA according to 1987 American College of Rheumatology criteria. 30 Significant hypertension or diabetes was the exclusion criterion. Patients were subgrouped by disease activity into a group with active disease, reflected by a disease activity score using 28 joint counts (DAS28) 31 Ն3.2 (nϭ36) and a group with low disease activity or inactive disease (DAS Ͻ3.2, nϭ16). Disease activity variables, such as joint counts and global assessments, were evaluated by an independent assessor. Sixteen healthy volunteers (some of the authors and nonmedical persons known to the authors who had neither a history of ischemic cardiovascular events, inflammatory disease, or autoimmune disease nor any other chronic disease) were selected to be matched by age and sex and served as the healthy reference (HR) population. The characteristics of patients and HRs are summarized in the Table. The local ethics committee approved the study, and patients and HRs provided informed consent for this research. Surrogates of inflammatory response (erythrocyte sedimentation rate and CRP), rheumatoid factor, and erythropoietin (Epo) were determined according to standard procedures.
As shown in the Table, at the time of the study in the active-RA group, 2 patients were not receiving any DMARDs, 20 were receiving methotrexate (MTX), 5 were receiving leflunomide, 2 were receiving salazopyrine, and 3 patients were being treated with a combination of DMARDs; 4 patients were receiving subcutaneous or intravenous TNF-blocker therapy (etanercept or infliximab with MTX). Twenty-three of the patients were also being treated with low-dose prednisolone (Յ10 mg/d).
Flow Cytometry Analysis
Fluorescence-activated cell sorting (FACS) analyses of EPCs were performed as described by Vasa and coworkers. 26 In brief, 100 L of peripheral blood was incubated with a biotinylated monoclonal antibody against human KDR (Becton Dickinson), followed by staining with streptavidin-Quantum Red conjugate (Sigma). Samples were then incubated with fluorescein isothiocyanate (FITC)-conjugated CD34 (BD Pharmingen) and phycoerythrin-conjugated AC133 phycoerythrin (Miltenyi) antibodies. Control stainings were performed with isotype-matched antibodies. Incubation was followed by lysis and fixation with BD lysing solution. Acquisition was then performed on a Becton Dickinson FACS flow cytometer (FACScan) and included 100 000 to 300 000 events per sample. Cells positive for CD34/KDR/AC133 within the lymphocyte population were characterized as EPCs. These analyses were performed for all 52 patients and 16 HRs.
CFU Assay
Circulating EPCs were also quantified by the colony-forming unit (CFU) assay as described by Hill et al 27 in randomly selected, active-disease (nϭ10) and inactive-disease (nϭ9) RA patients and in 10 HRs. For this purpose, 5ϫ10 6 PBMCs obtained by density gradient centrifugation on Ficoll-Paque (Amersham Biosciences) were plated on fibronectin-precoated, 6-well plates and cultivated in growth medium 199 (Gibco) containing 20% fetal calf serum and penicillin (100 U/mL)/streptomycin (100 g/mL, Gibco) for 48 hours. Nonadherent cells were then recollected, and 10 6 cells/well were replated onto fibronectin-coated, 24-wells plates (Nunc) and cultured in duplicate samples for 7 days in growth medium that was changed every 3 days. CFUs, characterized by a central cluster surrounded by emerging cells, were then counted. Confirmation of endothelial cell lineage derivation of the CFUs was performed by immunostaining with biotinylated anti-KDR, followed by streptavidin-Quantum Red and FITC-conjugated CD34.
CAC Culture Assay
In another subgroup comprising 9 active-and 6 inactive-RA patients as well as 6 HRs, CACs, known to be derived mainly from the monocyte/leukocyte lineage 24 and attributed with proangiogenic effects, 32 were quantified by culture assay. In brief, PBMCs were isolated by density gradient centrifugation on Ficoll-Paque. PBMCs (4ϫ10 6 /well) were plated on 24-well culture plates (Nunc) coated with fibronectin in 1 mL endothelial basal medium-2 supplemented with endothelial growth medium-2 single quots (both from Cambrex Bio Science) containing fetal bovine serum, hydrocortisone, human VEGF-A, human FGF-B, human epidermal growth factor, insulinlike growth factor-1, and ascorbic acid in appropriate amounts. 26 After 4 days, nonadherent cells were removed by washing twice with phosphate-buffered saline, and adherent cells were again incubated in 1 mL medium. After 3 more days, EPCs were analyzed by incubating them with 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethylindocarbocyanine perchlorate-labeled, acetylated LDL (acLDL, Biomedical Technologies) for 3 hours and subsequent fixation with 4% paraformaldehyde for 20 minutes. Cells were then incubated for 1 hour with FITC-labeled Ulex europaeus agglutinin I (lectin, 10 g/mL, Sigma). Three randomly selected, high-power fields were
Characteristics of RA Patients and HRs
Age, y 52Ϯ17 55Ϯ15 53Ϯ12
Female, % 81 81 86
Smoker, % 44 13 22 Statin therapy, % 6 13 6
Disease duration, y
Other DMARD, % ⅐ ⅐ ⅐ 37 28
RF indicates rheumatoid factor. All other abbreviations are as defined in text. Data are presented as meanϮSD.
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evaluated by fluorescence or confocal microscopy. Only cells with double-positive staining for acLDL and lectin were counted as CACs. 24, 26 To exclude the possibility that the results had been influenced by changes in monocyte counts, we also performed differential blood counts for each donor. To confirm CAC derivation from the monocyte/leukocyte lineage, expression of CD11a, CD11b, CD14, and CD45 within the CAC population was measured by FACS analysis.
Enzyme-Linked Immunosorbent Assays
VEGF, bFGF, TNF, TNF receptors 1 and 2 (TNFR-I and TNFR-II), and Epo were quantified in the sera of 31 to 40 patients with RA and in 11 to 16 HRs with the use of commercial ELISA kits (TNF, Biosources; all others, R&D Systems). The minimum levels of detection were as follows: 5.0 pg/mL (VEGF), 0.22 pg/mL (bFGF), 3.0 pg/mL (TNF), 0.77 pg/mL (TNFR-I), 0.6 pg/mL (TNFR-II), and 0.6 mU/mL (Epo).
Statistical Evaluation
All data are presented as meanϮSEM, unless stated otherwise. Statistical evaluations were performed with SPSS for Windows, version 8.0 (SPSS Inc). Data were evaluated with a normality test, equal variance test, and Student's t test. Data not normally distributed were analyzed by nonparametric methods. When Ͼ2 groups were compared, 1-way ANOVA was used (given equality of variances). Post hoc Bonferroni-adjusted group comparisons were performed when appropriate. A probability value Ͻ0.05 was considered statistically significant.
Results
CD34/KDR/AC133-Positive Cells Are Decreased in Active RA
When PBMCs were analyzed by flow cytometry for the presence of EPCs, CD34/KDR/AC133-positive cells were found to be significantly decreased in patients with active RA compared with matched HRs ( Figure 1A , 0.045Ϯ0.008% in the HR group versus 0.026Ϯ0.002% in RA patients, PϽ0.05). The frequency of circulating EPCs in patients with low disease activity or inactive disease (0.052Ϯ0.006%) was comparable to that of HRs but differed significantly from that of active-RA patients (PϽ0.002). In fact, EPC levels in peripheral blood were correlated inversely with disease activity as assessed by the DAS28 (rϭϪ0.38, PϽ0.01, Figure  1B ). When the DAS28 subcomponents were analyzed further, EPC levels were correlated inversely with swollen (rϭϪ0.39, PϽ0.01) and tender (rϭϪ0.45, PϽ0.005) joint counts, but not with ESR and the global assessment.
Effects of DMARDs: Patients Treated With Anti-TNF Show Normal EPC Frequencies
Subanalyses performed of active-RA patients treated with different DMARDs suggested that as long as the disease was active, therapy with traditional DMARDs had no impact on EPC levels (Figure 2A ). Patients treated with MTX or those receiving either no DMARD or DMARDs other than MTX showed EPC quantities close to the mean of all active-RA patients (stated earlier). In contrast, among patients with DAS Ͻ3.2, regardless of therapy, circulating EPC proportions were similar to those in HRs (Figure 2A ). However, there was one exception: Among patients with active disease who were receiving TNF-blocker therapies, EPC levels (0.045Ϯ0.007%) were comparable to those of HRs and patients with low disease activity (Figure 2A ), even though their DAS scores were similar to those of all other patients with active disease (5.57Ϯ0.81 versus 5.04Ϯ0.19). As shown in Figure 2B , patients on low-dose steroid treatment did not differ from patients without steroids in regard to their EPC levels (Pϭ0.93).
CFU Assays Confirm a Reduction of EPCs in RA
When the CFUs ( Figure 3A and 3B, which shows CFUs by inverted microscopy) were counted for HRs and for patients with active disease (DAS28Ն3.2) and low disease activity (DAS28Ͻ3.2), the flow cytometric observations of EPC depletion in active RA were confirmed: Mean CFU counts were significantly lower in patients with active RA (5Ϯ2/ well) when compared with HR (18Ϯ5/well, PϽ0.05). In contrast, CFU counts among patients with low disease activity were twice as high (14Ϯ4/well) as those of patients with active RA and statistically did not differ from the counts of HRs (Pϭ0.95, Figure 3C ).
CAC Assays Indicate Decreased Angiogenic Potential of CD14-Positive Cells in RA
Cultivation of EPCs from a group of 9 RA patients with a DAS28 Ն3.2, from 6 patients with a DAS28 Ͻ3.2, and from 6 HRs again resulted in a significantly reduced number of EPCs in the cultures of active-RA patients. As shown in Figure 4 , after 7 days in culture, cells positive for lectin and acLDL, representing CACs, were found to be reduced by almost 90% compared with those from HRs (mean of 52Ϯ16 versus 7Ϯ2 acLDL/lectin-positive cells per high-power field, PϽ0.005). In patients with low disease activity, the mean of positive cells detected in culture assays was 25Ϯ5, which was not significantly different from that of HRs (Pϭ0.45, Figure  4 ). In Figure 5 , representative confocal fluorescence microscopy images of double staining for lectin and acLDL are shown. Relative monocyte counts in the differential blood counts, which could have influenced the results in the CAC assay, indicated no significant differences among the 3 groups (7.7Ϯ0.5% in HRs, 7.8Ϯ1.2% in inactive-RA patients, and 6.5Ϯ0.5% in active-RA patients). FACS analysis of CD11a, CD11b, and CD14 as well as CD45 expression confirmed that the majority of CACs was of leukocyte/ monocyte origin (data not shown).
Enzyme-Linked Immunosorbent Assays
bFGF serum levels were significantly increased among active-RA patients (9.7Ϯ1.0 pg/mL) when compared with HRs (3.6Ϯ1.3 pg/mL, PϽ0.0005) but were not detectable in inactive-RA patients. Likewise, VEGF levels were much higher among patients with active RA (629Ϯ69 pg/mL) compared with patients with low DAS (37.5Ϯ10.1 pg/mL, PϽ0.0005). In the groups of active-and inactive-disease patients as well as in the HR group, bFGF and VEGF levels showed no correlation with EPC levels. Furthermore, serum Epo levels were significantly increased in the group of active-RA patients (22Ϯ5 mU/mL) compared with HRs (10Ϯ1 mU/mL, PϽ001), and RA patients with low activity had intermediate levels (16Ϯ2 mU/mL). Interestingly, in active-RA patients, Epo values also showed a correlation with CRP levels (rϭ0.505, PϽ0.005), but like bFGF and VEGF, not with EPC levels (not shown). TNF serum levels were significantly increased among RA patients with a DAS Ն3.2 (29Ϯ9 versus 8Ϯ4 pg/mL in HRs, PϽ0.002, data not shown) and were not detectable in patients with low disease activity or inactive disease. TNF levels showed no correlation with other serological surrogates of angiogenesis. However, when EPC quantities from patients with normal (Ͻ15 pg/mL) and high (Ն15 pg/mL) TNF levels were compared, 33 patients with high serum TNF values had significantly lower EPC levels (0.023Ϯ0.003% versus 0.040Ϯ0.005%, PϽ0.05, Figure 6 ). In accordance with the findings for serum TNF, serum levels of TNFR-I and -II also were significantly increased in active-RA patients compared with the HR group (TNFR-I, 2374Ϯ183 versus 1498Ϯ121 Figure 2 . Lack of effect of DMARD and glucocorticoid therapy on EPC levels, except for TNF blockade. A, In group of active-RA patients (frequency of EPCs in total cell population, 0.026Ϯ0.002%, nϭ36), those treated with TNF blockers (0.045Ϯ0.007%, nϭ4) showed EPC frequency comparable to HRs (nϭ16) and to patients with low disease activity (nϭ16, see Figure 1A ). MTX (nϭ20 in active RA, nϭ10 in inactive RA) or other DMARDs (nϭ12 in active RA and nϭ6 in inactive RA) had no effect on circulating EPCs in active disease (ANOVA PϽ0.005). B, In active-RA, treatment with low-dose steroid (prednisolone Յ10 mg/d) did not affect EPC levels (0.026Ϯ0.004% in both groups, nϭ23 with and nϭ13 without [w/o] steroid treatment, Pϭ0.93). All other abbreviations are as defined in text.
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pg/mL, PϽ0.01; TNFR-II, 4150Ϯ113 versus 3633Ϯ145 pg/mL, PϽ0.02). In the group of active-RA patients, levels of both soluble TNF receptors showed a significant correlation with CRP (TNFR-I, rϭ0.434, PϽ0.02; TNFR-II, rϭ0.387, PϽ0.05), but there was no relation with EPC levels.
Discussion
Our data demonstrate a depletion of peripheral EPCs in patients with active RA. This observation was consistent, whether EPCs were determined by flow cytometry (CD34/ KDR/AC133-positive cells), CFU assay, or CAC assay. Moreover, EPC levels were inversely related to disease activity. In contrast, inactive RA was not associated with a significant reduction of EPC frequencies compared with those in HRs. However, this conclusion may be limited by relatively low power because of the small sample size. Because RA patients with active disease have a high propensity to suffer from cardiovascular disorders, especially myocardial infarction, 34 and because EPC levels are correlated inversely with cardiovascular risk factors, 26 our findings support these associations. Importantly, patients with low disease activity had normal EPC levels, in line with indications of reduced cardiovascular mortality among patients treated effectively with DMARDs 7 and with the very recent finding of EPC inhibition by CRP. 35 Interestingly, whereas Epo has been shown to mobilize EPCs, 36, 37 circulating EPCs were low in RA patients, despite increased Epo concentrations, and there was no correlation between Epo and EPC levels; this may be partly related to Epo resistance, as previously described in RA. 38 However, Epo levels were correlated with CRP.
None of the patients studied had known cardiovascular abnormalities. The percentage of persons taking hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), which are known to increase EPC numbers, 39 did not differ between HRs and RA patients. Moreover, serological markers of angiogenesis were increased among active-RA patients, as reflected by the high bFGF levels; VEGF was only mildly elevated. As with Epo, the observation that VEGF and bFGF increase EPC mobilization and proliferation 22, 40 does not appear to be reflected in patients with active RA. Thus, in RA, the levels of factors known to influence EPC mobilization or angiogenesis are elevated in relation to disease activity, but apparently their effects do not translate to the cellular level of EPCs. The observed decrease of VEGF and the low levels of TNF and bFGF in inactive-RA patients likely result from effective treatment leading to a normalization of their production. Among RA patients with high serum levels of TNF, circulating EPC levels were significantly decreased, suggesting a possible TNF dependence of the phenomenon observed in our study. This is further supported by the observation that EPC levels were within the normal range in patients treated with TNF blockers despite having high disease activity. It is also interesting in this context that a recent study reported a significant decrease of heart failure in RA patients treated with TNF blockers when compared with other therapies. 41 In contrast to RA, patients with gastric or breast cancer have numbers of circulating EPCs similar to those of HRs and have high VEGF levels 42 ; although similar to the findings reported here, patients suffering from another chronic disease associated with increased cardiovascular risk, diabetes mellitus type 1 and type 2, 43 are significantly deficient in EPCs compared with healthy individuals. 44, 45 In diabetes, serum VEGF levels are elevated, 46, 47 but as also shown here for RA, this does not affect EPC levels. In fact, because the synovial membrane is likely the major region of inflammation and of enhanced angiogenesis in RA, the observed increase of VEGF and bFGF may be due mainly to local production that contributes to new, intrasynovial vessel formation, 14 whereas other highly vascularized tissues like the heart or brain may not benefit from this event. It is conceivable that EPCs may be trapped in the inflamed synovial membrane. Thus, by virtue of the inflammatory process, EPCs may become reduced peripherally and therefore, be insufficiently available for other tissues, such as the heart. In fact, one part of this hypothesis is supported by very recent observations on EPC enrichment in the inflamed joint. 48 Such migrated EPCs could constitute an important source for new vessel formation in the synovium, and selective blockade of angiogenesis in the joints may be an interesting new therapeutic target.
In summary, the results of our study may open a new view: The decrease of EPCs and CACs in active RA might constitute an important event associated with the increased cardiovascular risk in RA patients. This risk as well as the decrease in EPCs may be primarily related to the increased TNF production known to be pathogenic in RA. 11, 49 In fact, also in this study, TNF levels were increased among patients with active RA and were correlated with surrogates of disease activity as well as low EPC frequencies. Consequently, effective therapy leading to low disease activity, as well as blockade of TNF, may lead to normalization of EPC levels. Thus, the mechanism by which effective DMARD therapy as well as TNF blockade may normalize the cardiovascular risk 7,41 might at least partly be related to normalization of the availability of EPCs. Figure 6 . RA patients with high TNF levels have low EPC frequencies. EPC levels (detected by FACS analysis) in RA patients with normal serum TNF levels (nϭ26) were significantly higher than in patients (nϭ14) with high (Ն15 pg/mL) TNF levels (0.040Ϯ0.005% vs 0.023Ϯ0.003%, PϽ0.05). Abbreviations are as defined in text.
